BCRX FY 2023 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$331M+22.4% YoY

Gross Profit

$327M98.6% margin

Operating Income

-$104M-31.3% margin

Net Income

-$227M-68.4% margin

EPS (Diluted)

$-1.18

Cash Flow

Operating Cash Flow

-$95M

Free Cash Flow

-$97M

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$517M

Total Liabilities

$972M

Stockholders' Equity

-$456M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$331M	$271M	+22.4%
Gross Profit	$327M	$264M	+23.7%
Operating Income	-$104M	-$148M	+30.1%
Net Income	-$227M	-$247M	+8.3%